Related Experiment Video
Updated: Jun 22, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth
Michael H Muders1, Pawan K Vohra, Shamit K Dutta
1Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Purpose:
Various studies have shown the importance of the GAIP interacting protein, COOH-terminus (GIPC, also known as Synectin) as a central adaptor molecule in different signaling pathways and as an important mediator of receptor stability. GIPC/Synectin is associated with different growth-promoting receptors such as insulin-like growth factor receptor I (IGF-IR) and integrins. These interactions were mediated through its PDZ domain. GIPC/Synectin has been shown to be overexpressed in pancreatic and breast cancer. The goal of this study was to show the importance of GIPC/Synectin in pancreatic cancer growth and to evaluate a possible therapeutic strategy by using a GIPC-PDZ domain inhibitor. Furthermore, the effect of targeting GIPC on the IGF-I receptor as one of its associated receptors was tested.
Experimental Design:
The in vivo effects of GIPC/Synectin knockdown were studied after lentiviral transduction of luciferase-expressing pancreatic cancer cells with short hairpin RNA against GIPC/Synectin. Additionally, a GIPC-PDZ--targeting peptide was designed. This peptide was tested for its influence on pancreatic cancer growth in vitro and in vivo.
Results:
Knockdown of GIPC/Synectin led to a significant inhibition of pancreatic adenocarcinoma growth in an orthotopic mouse model. Additionally, a cell-permeable GIPC-PDZ inhibitor was able to block tumor growth significantly without showing toxicity in a mouse model. Targeting GIPC was accompanied by a significant reduction in IGF-IR expression in pancreatic cancer cells.
Conclusions:
Our findings show that targeting GIPC/Synectin and its PDZ domain inhibits pancreatic carcinoma growth and is a potential strategy for therapeutic intervention of pancreatic cancer.
Insights
Targeting GAIP interacting protein, COOH-terminus (GIPC/Synectin) and its PDZ domain effectively inhibits pancreatic cancer growth. A novel GIPC-PDZ inhibitor shows therapeutic potential without toxicity, offering a new strategy for pancreatic cancer intervention.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- GAIP interacting protein, COOH-terminus (GIPC/Synectin) acts as a key adaptor molecule in signaling pathways and receptor stability.
- GIPC/Synectin interacts with growth-promoting receptors like IGF-IR and integrins via its PDZ domain.
- Overexpression of GIPC/Synectin is observed in pancreatic and breast cancers.
Purpose of the Study:
- To investigate the role of GIPC/Synectin in pancreatic cancer growth.
- To evaluate a GIPC-PDZ domain inhibitor as a potential therapeutic strategy.
- To assess the impact of targeting GIPC on the IGF-I receptor.
Main Methods:
- In vivo studies using lentiviral transduction and short hairpin RNA to knockdown GIPC/Synectin in pancreatic cancer cells.
- Design and in vitro/in vivo testing of a cell-permeable GIPC-PDZ targeting peptide.
- Assessment of IGF-IR expression following GIPC targeting.
Main Results:
- GIPC/Synectin knockdown significantly inhibited pancreatic adenocarcinoma growth in an orthotopic mouse model.
- The GIPC-PDZ inhibitor demonstrated significant tumor growth blockade in vivo without observable toxicity.
- Targeting GIPC led to a significant reduction in IGF-IR expression in pancreatic cancer cells.
Conclusions:
- Targeting GIPC/Synectin and its PDZ domain is a promising strategy for inhibiting pancreatic carcinoma growth.
- A GIPC-PDZ inhibitor represents a potential therapeutic intervention for pancreatic cancer.
- The study highlights the critical role of GIPC/Synectin in pancreatic cancer progression.
